Abcellera Biologics Intrinsic Value Calculator – ABCELLERA BIOLOGICS Reports Record Earnings for Q2 of FY2023 on June 30th

🌥️Earnings Overview

ABCELLERA BIOLOGICS ($NASDAQ:ABCL) reported a total revenue of USD 10.1 million for Q2 of FY2023 on June 30 2023, a 78.1% decrease year over year. Their net income suffered too, dropping to USD -30.5 million from -6.8 million the previous year.

Market Price

The stock opened at $6.9 and closed at $7.0, a surge of 0.4% from its prior closing price of 6.9. This record high earning was supported by ABCELLERA BIOLOGICS’ ability to create innovative treatments with the help of AI-Enabled Technology. The company is focused on leveraging the power of artificial intelligence to accelerate the discovery of new drugs and medical treatments. The use of AI-Enabled Technology is proving to be beneficial in ABCELLERA BIOLOGICS’ success as they continue to be one of the most profitable companies in the biotechnology industry. With the help of AI-Enabled Technology, the company is able to quickly identify molecules that can be used to develop new treatments.

This technology is also helping ABCELLERA BIOLOGICS to reduce costs and speed up clinical trials for their products. The company’s success has been attributed to their strong financial performance and the increasing demand for their products. This indicates that the company is well positioned to continue its growth in the future. The company’s success is expected to continue in the future as they look to further leverage AI-Enabled Technology to create innovative treatments. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Abcellera Biologics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Abcellera Biologics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Abcellera Biologics. More…

Key Ratios Snapshot

Some of the financial key ratios for Abcellera Biologics are shown below. More…

Analysis – Abcellera Biologics Intrinsic Value Calculator

GoodWhale has conducted a comprehensive analysis of ABCELLERA BIOLOGICS‘s fundamentals. Our proprietary Valuation Line values ABCELLERA BIOLOGICS shares at around $16.0, which is significantly higher than the current trading price of $7.0. This means that ABCELLERA BIOLOGICS stock is currently undervalued by 56.3%. We believe that this provides an excellent opportunity for investors to enter the market. More…

Peers

Its mAbs target CD3, CD20, HER2, EGFR and other proteins. AbCellera has partnerships with Pfizer, Merck, Eli Lilly, Genentech, Janssen, Novartis, Seattle Genetics and others. The company was founded in 2012 and is headquartered in Vancouver, Canada. Ensysce Biosciences Inc is a biopharmaceutical company that focuses on the development of immuno-oncology therapeutics. Its products include ENS-761, ENS-784 and ENS-861. The company was founded in 2007 and is headquartered in La Jolla, CA. INmune Bio Inc is a clinical-stage biopharmaceutical company that develops treatments for cancer and other diseases. Its products include INK-128, INK-185 and INB-1008. The company was founded in 2015 and is headquartered in La Jolla, CA. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company that develops immuno-oncology therapeutics. Its products include SON-101, SON-201 and SON-301. The company was founded in 2016 and is headquartered in New York, NY.

– Ensysce Biosciences Inc ($NASDAQ:ENSC)

Ensysce Biosciences Inc is a clinical stage biopharmaceutical company. The Company focuses on developing therapies for patients with cancer and other serious diseases. Ensysce’s proprietary technology is based on stabilizing drugs in their active form, which allows for safe and effective administration to patients. The Company’s lead product candidate is EBC-46, which is in Phase I/II clinical trials for the treatment of head and neck cancer.

– INmune Bio Inc ($NASDAQ:INMB)

Innate Immunotherapeutics is a clinical-stage biotechnology company developing medicines to treat autoimmune and inflammatory diseases. The company has a market cap of $126.88M as of 2022 and a Return on Equity of -27.44%. Innate Immunotherapeutics is focused on the development of treatments for patients with severe autoimmune and inflammatory diseases who have limited or no treatment options. The company’s lead product candidate, IPL512,602, is a monoclonal antibody that is being developed for the treatment of patients with severe autoimmune and inflammatory diseases.

– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of novel, small molecule therapeutics for the treatment of cancer. The company’s product pipeline includes SNT-100, SNT-101, and SNT-102. Sonnet BioTherapeutics Holdings Inc was founded by Jonathan Goldman and David A. Goldman in 2015 and is headquartered in New York, NY.

Summary

ABCELLERA BIOLOGICS reported their Q2 FY2023 earnings with total revenue of USD 10.1 million, a 78.1% decrease year over year. Net income decreased to USD -30.5 million from -6.8 million the previous year. This reflects a difficult financial period for the company due to the pandemic and other economic factors. Investors should consider thoroughly reviewing their balance sheet and financial statements in order to assess the company’s current financial situation and future outlook.

Additionally, investors should pay attention to the company’s strategy for turning around performance in the coming quarters.